Legend Biotech Corporation
LEGN · Nasdaq · United States
Share price · LEGN
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when LEGN's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 10 Nov 2026-16.0%
- 18 Jun 2026-16.7%
- 2 Jun 2026+42.2%
- 12 May 2026+10.5%
- 11 May 2026-9.0%
Nothing announced by LEGN that day or the session before.
- 4 May 2026+12.3%
- 20 Apr 2026+18.4%
Nothing announced by LEGN that day or the session before.
- 15 Apr 2026+9.8%
- 6 Mar 2026+6.9%
Nothing announced by LEGN that day or the session before.
- 23 Feb 2026+9.0%
Nothing announced by LEGN that day or the session before.
Share of unusual movement by asset
For each asset, the share of LEGN's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | BCMACell therapy | Multiple Myeloma | |
| Preclinical / Unstaged | FCRL5Cell therapy | Multiple Myeloma |
Upcoming events
(5 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (2)
2028 (1)
April 2028 (1)
What to watch
2029 (1)
February 2029 (1)
What to watch
2030 (1)
September 2030 (1)
What to watch
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (7)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-Q3 | $11M | $113M | $279M | $40M$29M operating cash flow | report ↗ |
Legend Biotech Corporation reported revenue of $10.5M, down 39.6% YoY, R&D spend of $113.15M, up 18.5% YoY, cash and equivalents of $278.89M, and a net loss of $39.69M for Q3 2025.
Figures only: this period's report disclosed no narrative text
View 6 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-Q2 | $35M | $98M | $267M | $125M-$13M operating cash flow | report ↗ |
| 2025-Q1 | $9.4M | $102M | $442M | $101M-$104M operating cash flow | report ↗ |
| 2024-Q3 | $17M | $96M | $459M | $125M-$76M operating cash flow | report ↗ |
| 2024-Q2 | $93M | $113M | $201M | $18M-$1.6M operating cash flow | report ↗ |
| 2024-Q1 | $16M | $101M | $898M | $60M$16M operating cash flow | report ↗ |
| 2023-Q1 | — | $85M | $660M | $112M-$139M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $1.0B | $415M | $902M | $74M-$100M operating cash flow | report ↗ |
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $145M | $414M | $287M | $44M-$144M operating cash flow | report ↗ |
| 2023-FY | $35M | $382M | $1.3B | $130M-$393M operating cash flow | report ↗ |
| 2022-FY | $117M | $336M | $786M | $112M-$201M operating cash flow | report ↗ |
| 2021-FY | $90M | $313M | $689M | $97M-$198M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 2 purchases ($183K), 5 sales ($567K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-13 | Salovey Peter · director | Open-market purchase | 10,000 | $8.95 | $90K | Form 4 |
| 2026-11-12 | Salovey Peter · director | Open-market purchase | 10,000 | $9.38 | $94K | Form 4 |
| 2026-09-29 | Sanders Corazon (Corsee) D. · director | Open-market sale | 27,370 | $9.46 | $259K | Form 4 |
| 2026-09-24 | Sanders Corazon (Corsee) D. · director | Award / grant | 20,986 | — | — | Form 4 |
| 2026-09-24 | Ji Darren Xiaohui · director | Award / grant | 28,330 | — | — | Form 4 |
| 2026-09-24 | Casey Patrick John · director | Award / grant | 20,986 | — | — | Form 4 |
| 2026-09-24 | Mao Li · director | Award / grant | 20,986 | — | — | Form 4 |
| 2026-09-24 | Heyman Tomas J. · director | Award / grant | 20,986 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 190 reporting institutions held 96.1M shares ($1.7B, 26.0% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | FMR LLC | 25,696,740 | $464.9M |
| 2 | DEERFIELD MANAGEMENT COMPANY, L.P. | 7,687,638 | $139.1M |
| 3 | SUVRETTA CAPITAL MANAGEMENT, LLC | 7,581,029 | $137.1M |
| 4 | HHLR ADVISORS, LTD. | 5,984,550 | $108.3M |
| 5 | WESTFIELD CAPITAL MANAGEMENT CO LP | 5,763,475 | $104.3M |
| 6 | BlackRock, Inc. | 4,684,543 | $84.7M |
| 7 | Point72 Asset Management, L.P. | 3,886,017 | $70.3M |
| 8 | First Beijing Investment Ltd | 2,296,335 | $41.5M |
| 9 | Artisan Partners Limited Partnership | 2,254,488 | $40.8M |
| 10 | TWO SIGMA INVESTMENTS, LP | 1,890,396 | $34.2M |
| 11 | Kynam Capital Management, LP | 1,576,295 | $28.5M |
| 12 | STATE STREET CORP | 1,498,372 | $27.1M |
| 13 | GOLDMAN SACHS GROUP INC | 1,464,112 | $26.5M |
| 14 | Davern Capital Partners, LP | 1,314,748 | $23.8M |
| 15 | Patient Square Capital LP | 990,000 | $17.9M |